BIOMAT Database Logo BIOMAT Database Logo

Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. 2006

Susan H Eshleman, and Dana Jones, and Justin Galovich, and Ellen E Paxinos, and Christos J Petropoulos, and J Brooks Jackson, and Neil Parkin
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. seshlem@jhmi.edu

We analyzed the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) susceptibility of 29 subtype A HIV-1 clones isolated from 10 Ugandan women after single-dose nevirapine (NVP) administration. Six clones had no NNRTI resistance-associated mutations ("wild type"), eight had K103N, nine had Y181C, five had G190A, and one had Y181S. Three clones displayed unexpected phenotypic drug susceptibility/resistance based on their RT genotypes. One wild-type clone had reduced susceptibility to NVP, delavirdine (DLV), and efavirenz (EFV), one clone with K103N was susceptible to all three NNRTIs, and one clone with G190A had extreme hypersusceptibility to DLV. Three unusual HIV-1 RT amino acid substitutions may have contributed to the unexpected phenotypes of the clones: I31T, N136S, and N265D. These polymorphisms were rarely detected among 47,900 HIV-1 genotypes from clinical samples of predominantly United States origin. Further studies are needed to define the genetic correlates of antiretroviral drug resistance in nonsubtype B HIV-1.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D002999 Clone Cells A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed) Clones,Cell, Clone,Cells, Clone,Clone,Clone Cell
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000480 Alkynes Hydrocarbons with at least one triple bond in the linear portion, of the general formula Cn-H2n-2. Acetylenic Compounds,Alkyne,Acetylenes
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D048588 Benzoxazines OXAZINES with a fused BENZENE ring. Benzoxazine,Benzoxazinoid,Benzoxazinone,Benzoxazinones,Benzoxazinoids

Related Publications

Susan H Eshleman, and Dana Jones, and Justin Galovich, and Ellen E Paxinos, and Christos J Petropoulos, and J Brooks Jackson, and Neil Parkin
Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.
May 2011, Antimicrobial agents and chemotherapy,
Susan H Eshleman, and Dana Jones, and Justin Galovich, and Ellen E Paxinos, and Christos J Petropoulos, and J Brooks Jackson, and Neil Parkin
HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.
January 1996, Biochemistry,
Susan H Eshleman, and Dana Jones, and Justin Galovich, and Ellen E Paxinos, and Christos J Petropoulos, and J Brooks Jackson, and Neil Parkin
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.
April 2011, Antimicrobial agents and chemotherapy,
Susan H Eshleman, and Dana Jones, and Justin Galovich, and Ellen E Paxinos, and Christos J Petropoulos, and J Brooks Jackson, and Neil Parkin
Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.
May 2011, AIDS (London, England),
Susan H Eshleman, and Dana Jones, and Justin Galovich, and Ellen E Paxinos, and Christos J Petropoulos, and J Brooks Jackson, and Neil Parkin
A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.
November 2014, AIDS (London, England),
Susan H Eshleman, and Dana Jones, and Justin Galovich, and Ellen E Paxinos, and Christos J Petropoulos, and J Brooks Jackson, and Neil Parkin
Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.
July 2015, Journal of virology,
Susan H Eshleman, and Dana Jones, and Justin Galovich, and Ellen E Paxinos, and Christos J Petropoulos, and J Brooks Jackson, and Neil Parkin
HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
October 2010, HIV medicine,
Susan H Eshleman, and Dana Jones, and Justin Galovich, and Ellen E Paxinos, and Christos J Petropoulos, and J Brooks Jackson, and Neil Parkin
Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.
September 2014, Viruses,
Susan H Eshleman, and Dana Jones, and Justin Galovich, and Ellen E Paxinos, and Christos J Petropoulos, and J Brooks Jackson, and Neil Parkin
Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug.
February 1992, AIDS research and human retroviruses,
Susan H Eshleman, and Dana Jones, and Justin Galovich, and Ellen E Paxinos, and Christos J Petropoulos, and J Brooks Jackson, and Neil Parkin
Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.
February 2015, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!